CoChat
Sign Up
Cited by 115Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.

Drug Treatment of the Overweight Patient

Bray, George A., Ryan, Donna H.·2007·Gastroenterology
DOI 10.1053/j.gastro.2007.03.053
Open this paper in CoChat — free account

Abstract

Three medications with approval for long-term use in the treatment of obesity are currently available in the United States. Sibutramine (U.S. Food and Drug Administration [FDA] approved in 1997), orlistat (FDA approved in 1999), and rimonabant (available in Europe and given FDA approvable status in 2006 and expected to be marketed in 2007) represent modern approaches to medications used adjunctively for weight management. As demonstrated in large clinical trials of 2 to 4 years' duration, these medications significantly increase weight loss compared with placebo; weight loss with these drugs reaches a nadir between 20 and 28 weeks; weight loss, averaged 8%-10%, with the placebo contributing 4%-6% of that. Weight maintenance is demonstrated as long as adherence to medication continues. All medications have side effects that need to be considered. For sibutramine, there is a rise in blood pressure and heart rate that may require discontinuation of the drug in a small percent of patients. For orlistat, steatorrhea produces the principal gastrointestinal side effects. Rimonabant appears to have a favorable safety and tolerability profile. Nausea and gastrointestinal symptoms are the chief tolerability issue, but they are usually self-limited. In addition there are several drugs and drug combinations in phase 2 or phase 2 trials that will be reported on in the coming years.

Overview

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2007.03.053

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 90 references

Research works printed but not linked: 3

  1. Brandt, 2004, Intranasal peptide YY 3-36: phase 1 dose ranging and dose sequencing studies, Obes Res, 12, A28
  2. Dunk, 2002, Increased fecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962, Int J Obes Relat Metab Disord, 26, S135
  3. Kopelman, 2006, A randomised, placebo-controlled, trial of cetilistat (ATL-962), a novel lipase inhibitor and orlistat (Xenical©) for the management of obese type 2 diabetic patients, Diabetes Metab, 55, A395

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Bray, G. A., & Ryan, D. H.
Affiliations
Pennington Biomedical Research Center (US)
ORCID
Ryan, Donna H.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2007-05
Volume
132
Issue
6
Pages
2239-2252
ISSN
0016-5085 (ISSN-L)
DOI
10.1053/j.gastro.2007.03.053
OpenAlex
W2066499225
Cited by
115
References
90
Citations by year
2026: 1 · 2025: 2 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 5 · 2014: 2 · 2013: 5 · 2012: 10
FWCI
1.70
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, anti-obesity drugs, sibutramine, orlistat, rimonabant, weight maintenance, adverse drug reactions, elevated blood pressure, steatorrhea, gastrointestinal tolerance, long-term drug safety
MeSH terms
Rimonabant, Orlistat, Animals, Cyclobutanes, Humans, Lactones, Obesity, Piperidines, Pyrazoles, Treatment Outcome, Clinical Trials, Phase II as Topic, Anti-Obesity Agents, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review